News Quantified

CGEN – compugen ltd. - ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Compugen to Present New Clinical Data at SITC 2024

Compugen to Present at Single Cell Genomics 2024 Conference

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

-4.4%

BEAT

-15.9%

BEAT

-17.5%

BEAT

-5.7%

MISS

Top News Gainers

3/9 Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.7%

3/17 Medicxi Bolsters and Expands Team with Senior Industry Leaders 12.8%

3/9 Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study 12.1%

11/5 Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019 11.1%

4/14 Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting 10.6%

4/28 Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 9.7%

4/6 Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies 9.1%

4/17 Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%

4/10 Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 8.7%

2/20 Compugen Reports Fourth Quarter and Full Year 2019 Results 7.5%

Top News Decliners

3/11 Compugen Announces Commencement of Public Offering of Ordinary Shares -28.1%

3/13 Form 6-K COMPUGEN LTD For: Mar 13 -12.4%

5/20 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.170 ActVsEst 0.030 - Beat -9.2%

11/6 Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe -9.0%

2/24 Form 20-F COMPUGEN LTD For: Dec 31 -8.0%

2/21 Compugen Ltd. (NASDAQ: CGEN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock, up previously from $10.00. -6.1%

4/23 Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020 -6.1%

8/5 Form F-3 COMPUGEN LTD -5.3%

10/7 Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%

4/28 Compugen Ltd. (NASDAQ: CGEN) had its price target raised by analysts at SunTrust Banks, Inc. from $16.00 to $22.00. They now have a "buy" rating on the stock. -4.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day